Lei Xiao
Vorstandsvorsitzender bei Innovative Cellular Therapeutics Co., Ltd.
Profil
Lei Xiao is the founder of Innovative Cellular Therapeutics Co., Ltd.
He holds the titles of Chairman, Chief Executive, and Scientific Officer, which he has held since the company's founding in 2009.
Aktive Positionen von Lei Xiao
| Unternehmen | Position | Beginn |
|---|---|---|
Innovative Cellular Therapeutics Co., Ltd.
 Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then. | Vorstandsvorsitzender | 01.01.2009 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Innovative Cellular Therapeutics Co., Ltd.
Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then. | Health Technology |